FMA
TPST icon

FNY Managed Accounts’s Tempest Therapeutics TPST Stock Holding History

FNY Managed Accounts’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14
Closed -$208K – 521
2016
Q2 		$208K Buy
+14
New +$320K 0.19% 71

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FNY Managed Accounts's TPST Position: Q3 2016 in Review

FNY Managed Accounts sold out of Tempest Therapeutics (TPST) in Q3 2016, closing a stake of 14 shares — an estimated $208K sold.

FNY Managed Accounts first reported a position in TPST in Q2 2016 and held it in 1 quarter. The position peaked at $208K in Q2 2016. 80 funds tracked by Wall St. Rank hold TPST as of Q3 2016.

  • FNY Managed Accounts reported no remaining Tempest Therapeutics position as of Q3 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 14 Tempest Therapeutics shares in Q3 2016, an estimated $208K.
  • FNY Managed Accounts first reported a position in Tempest Therapeutics in Q2 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Tempest Therapeutics position peaked at $208K in Q2 2016.
  • 80 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2016.

Based on FNY Managed Accounts's 13F filing for Q3 2016, filed 18 Oct 2016.